Biomarkers Study in Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01666184|
Recruitment Status : Unknown
Verified August 2012 by National Health Research Institutes, Taiwan.
Recruitment status was: Enrolling by invitation
First Posted : August 16, 2012
Last Update Posted : August 16, 2012
Patients are eligible if (1) enrolled to TCOG 3207(2) received surgery or biopsy for pancreatic cancer; (3) willing to sign informed consent.
The pancreatic tumor, tissue specimen and blood sample before or after treatment will be collected from department of pathology, surgery or diagnostic medicine.
|Condition or disease|
|Biomarkers Study in Pancreatic Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||270 participants|
|Official Title:||Biomarkers Study in Pancreatic Cancer|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||December 2017|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01666184
|Principal Investigator:||Yi-Ming Shyr, M.D.||Taipei Veterans General Hospital, Taiwan|
|Principal Investigator:||Tsann-Long Hwang, M.D.||Chang Gung Memorial Hospital|
|Principal Investigator:||Ruey-Kuen Hsieh, M.D.||Mackay Memorial Hospital Taipei, Taiwan|